Tian Xia, Cai Hong, Zhu Yu-xian
National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing 100871, China.
Zhonghua Yi Xue Za Zhi. 2005 Jun 1;85(20):1410-3.
To investigate the imunogenicity and protective efficacy of the divalent DNA vaccine encoding the antigens MPT83 and MPT64 of Mycobacterium tuberculosis.
Two genes of the M. tuberculosis, MPT83 and MPT64, were amplified and cloned into the vector pJW4303. The vector containing the fusion gene DNA-MM and pJW4303 blank vector were transfected into CO57 cells. The expression of DNA-MM in the supernatant was detected by Western blotting. Thirty-six C57BL/6 mice were divided into 3 equal groups to be injected subcutaneously with the vector containing the fusion gene DNA-MM, pJW4303 blank vector, or bacillus of Calmette-Guerin vaccine (BCG) once a week for 3 weeks. Twelve mice were used as non-immunized controls. Blood samples were collected from the mice before and after every immunization to detect the titer of antibody by ELISA. Three weeks after the 3rd immunization 3 mice from each were killed and their spleens were taken out. The splenocytes were cultured and stimulated by the recombinant antigen to detect the concentrations of interferon (IFN)-gamma and interleukin (IL)-4. Six weeks after the 3rd immunization M. tuberculosis of the line H37Rv was injected intravenously into the mice. Eight weeks later, the mice were killed and their lungs and spleens were taken out. The tissues were cultured to calculate the numbers of M. tuberculosis.
Western blotting showed that the CO57 cells transfected with the vector containing the fusion gene expressed DNA-MM. ELISA showed that no antibody titer was detected before immunization in every group. The titer of MPT83 and MPT64 were increased to 1:200, 1:800, and 1:6400 3 weeks after the 1st, 2nd, and 3rd immunization respectively in the divalent group, increased to 1:800 3 weeks after the 3rd immunization in the BCG group, and remained 0 at any time points in the blank vector group. The IFN-gamma titer of the divalent group was 7520 pg/ml, significantly higher than that of the BCG group (6675.6 pg/ml, P < 0.05). The IL-4 concentration was basically the same and at the ng level in all groups. After challenge of H37Rv the bacterial loading in the lung was (2.21 +/- 0.032) x 10(5) in the divalent group, one thousandth of that in the blank vector group, and one tenth of that in the BCG group.
The divalent vaccine containing the antigens MPT83 and MPT64 effectively heightens the protective efficiency of vaccine against tuberculosis.
研究编码结核分枝杆菌抗原MPT83和MPT64的二价DNA疫苗的免疫原性和保护效力。
扩增结核分枝杆菌的两个基因MPT83和MPT64,并克隆至载体pJW4303。将含有融合基因DNA-MM的载体和pJW4303空载体转染至CO57细胞。通过蛋白质免疫印迹法检测上清液中DNA-MM的表达。将36只C57BL/6小鼠分为3组,每组12只,分别皮下注射含有融合基因DNA-MM的载体、pJW4303空载体或卡介苗(BCG),每周1次,共3周。12只小鼠作为未免疫对照。每次免疫前后采集小鼠血样,通过酶联免疫吸附测定(ELISA)检测抗体效价。第3次免疫3周后,每组处死3只小鼠,取出脾脏。培养脾细胞并用重组抗原刺激,检测干扰素(IFN)-γ和白细胞介素(IL)-4的浓度。第3次免疫6周后,经静脉向小鼠注射H37Rv株结核分枝杆菌。8周后,处死小鼠,取出肺和脾脏。对组织进行培养以计算结核分枝杆菌数量。
蛋白质免疫印迹法显示,转染含有融合基因载体的CO57细胞表达DNA-MM。ELISA显示,各组免疫前均未检测到抗体效价。二价疫苗组在第1、2、3次免疫后3周,MPT83和MPT64的抗体效价分别升至1:200、1:800和1:6400;卡介苗组在第3次免疫后3周抗体效价升至1:800;空载体组在任何时间点均为0。二价疫苗组的IFN-γ效价为7520 pg/ml,显著高于卡介苗组(6675.6 pg/ml,P<0.05)。各组IL-4浓度基本相同,均处于纳克水平。H37Rv攻击后,二价疫苗组肺内细菌载量为(2.21±0.032)×10⁵,为空载体组的千分之一,卡介苗组的十分之一。
含抗原MPT83和MPT64的二价疫苗可有效提高疫苗对结核病的保护效力。